{
    "organizations": [],
    "uuid": "c13274fa2f7de794a2e26ad2c8096238058fa1dd",
    "author": "",
    "url": "https://www.reuters.com/article/brief-delmar-pharmaceuticals-presents-po/brief-delmar-pharmaceuticals-presents-positive-updates-on-2-ongoing-clinical-trials-with-val-083-for-treatment-of-mgmt-unmethylated-gbm-idUSASC09W5X",
    "ord_in_thread": 0,
    "title": "BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17, 2018 / 6:08 PM / Updated 7 minutes ago BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM Reuters Staff 1 Min Read \nApril 17 (Reuters) - DelMar Pharmaceuticals Inc: \n* DELMAR PHARMACEUTICALS PRESENTS POSITIVE UPDATES ON TWO ONGOING CLINICAL TRIALS WITH VAL-083 FOR TREATMENT OF MGMT-UNMETHYLATED GBM \n* DELMAR PHARMACEUTICALS - NO DOSE-LIMITING TOXICITIES HAVE BEEN REPORTED FOLLOWING TREATMENT WITH MULTIPLE CYCLES OF VAL-083 Source text for Eikon: Further company coverage:",
    "published": "2018-04-17T21:07:00.000+03:00",
    "crawled": "2018-04-17T21:23:32.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "pharmaceutical",
        "present",
        "positive",
        "update",
        "ongoing",
        "clinical",
        "trial",
        "treatment",
        "gbm",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "delmar",
        "pharmaceutical",
        "inc",
        "delmar",
        "pharmaceutical",
        "present",
        "positive",
        "update",
        "two",
        "ongoing",
        "clinical",
        "trial",
        "treatment",
        "gbm",
        "delmar",
        "pharmaceutical",
        "toxicity",
        "reported",
        "following",
        "treatment",
        "multiple",
        "cycle",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}